TOKYO, Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be...
Hence then, the article about astellas to present first real world veozah fezolinetant data at 2025 annual meeting of the menopause society was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society )
Also on site :
- Nicki Minaj at risk of losing $20M Los Angeles home over assault debt battle
- 39,000 sub-commercial registrations, costing SR21 million, cancelled since April
- MARPAI RECOGNIZED AS 2025 TOP THIRD PARTY ADMINISTRATOR